Fierce JPM Week

The pharma and biotech industries stand at an inflection point unseen since the genomic revolution. After years of pandemic-fueled growth and subsequent market turmoil, companies are redefining how they will survive and thrive. Capital is scarcer. Regulators worldwide are rewriting the rules. Breakthrough therapies in oncology, rare diseases and obesity are upending competition, even as supply chains fray and manufacturing nationalism redraws the global map.